{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:01:40Z","timestamp":1782878500820,"version":"3.54.5"},"reference-count":42,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background and Aim: Hepatocellular carcinoma (HCC) recurrence rates after liver transplantation (LT) range between 8 and 20%. Alpha-fetoprotein (AFP) levels at transplant can predict HCC recurrence, however a defined cut-off value is needed to better stratify patients. The aim of this study was to evaluate the rate of HCC recurrence at our centre and to identify predictors, focusing on AFP. Methods: We retrospectively analysed 236 consecutive patients that were waitlisted for HCC who all met the Milan criteria from January 2001 to December 2017 at our liver transplant centre. A total of twenty-nine patients dropped out while they were waitlisted, and 207 patients were included in the final analysis. All survival analyses included the competing-risk model. Results: The mean age was 56.8 \u00b1 6.8 years. A total of 14% were female (n = 29\/207). The median MELD (model for end-stage liver disease) at LT was 12 (9\u201316). The median time on the waitlist was 92 (41\u2013170) days. The HCC recurrence rate was 16.4% (n = 34\/208). The mean time to recurrence was 3.3 \u00b1 2.8 years. The median AFP levels at transplant were higher in patients with HCC recurrence (p &lt; 0.001). At multivariate analysis, the AFP value at transplant that was greater than 25.5 ng\/mL (AUC 0.69) was a strong predictor of HCC recurrence after LT [sHR 3.3 (1.6\u20136.81); p = 0.001]. The HCC cumulative incidence function (CIF) of recurrence at 10 years from LT was significantly higher in patients with AFP &gt; 25.5 ng\/mL [34.3% vs. 11.5% (p = 0.001)]. Moreover, an increase in AFP &gt; 20.8%, was significantly associated with HCC recurrence (p = 0.034). Conclusions: In conclusion, in our retrospective study, the AFP level at transplant &gt; 25.5 ng\/mL and its increase greater than 20.8% on the waitlist were strong predictors of HCC recurrence after LT in a cohort of patients that were waitlisted within the Milan criteria. However further studies are needed to validate these data.<\/jats:p>","DOI":"10.3390\/cancers13235976","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T01:49:58Z","timestamp":1638150598000},"page":"5976","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pre-Transplant Alpha-Fetoprotein &gt; 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6417-3205","authenticated-orcid":false,"given":"Bianca","family":"Magro","sequence":"first","affiliation":[{"name":"Gastroenterology, Hepatology and Liver Transplantation, Department of Medicine-Papa Giovanni, XXIII Hospital, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pinelli","sequence":"additional","affiliation":[{"name":"Unit of Hepato-Biliary Surgery and Liver Transplantation, ASST Papa Giovanni XXIII, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"De Giorgio","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology and Liver Transplantation, Department of Medicine-Papa Giovanni, XXIII Hospital, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Luc\u00e0","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology and Liver Transplantation, Department of Medicine-Papa Giovanni, XXIII Hospital, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carrobio","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Baronio","sequence":"additional","affiliation":[{"name":"Unit of Hepato-Biliary Surgery and Liver Transplantation, ASST Papa Giovanni XXIII, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0268-3266","authenticated-orcid":false,"given":"Luca","family":"Del Prete","sequence":"additional","affiliation":[{"name":"Unit of Hepato-Biliary Surgery and Liver Transplantation, ASST Papa Giovanni XXIII, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Nounamo","sequence":"additional","affiliation":[{"name":"Unit of Hepato-Biliary Surgery and Liver Transplantation, ASST Papa Giovanni XXIII, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gianatti","sequence":"additional","affiliation":[{"name":"Pathology Unit, ASST Papa Giovanni XXIII, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Colledan","sequence":"additional","affiliation":[{"name":"Unit of Hepato-Biliary Surgery and Liver Transplantation, ASST Papa Giovanni XXIII, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology and Liver Transplantation, Department of Medicine-Papa Giovanni, XXIII Hospital, 24122 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1111\/j.1600-6143.2007.01965.x","article-title":"Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging","volume":"7","author":"Yao","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.3748\/wjg.v19.i36.6077","article-title":"Up-to-seven criteria for hepatocellular carcinoma liver transplantation: A single center analysis","volume":"19","author":"Lei","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00534-009-0162-y","article-title":"Liver transplantation for hepatocellular carcinoma: The Kyoto experience","volume":"17","author":"Takada","year":"2010","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.3748\/wjg.v21.i16.4933","article-title":"Prognostic roles of preoperative \u03b1-fetoprotein and des-\u03b3-carboxy prothrombin in hepatocellular carcinoma patients","volume":"21","author":"Meguro","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.3748\/wjg.v24.i45.5081","article-title":"Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm","volume":"24","author":"Au","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_11","unstructured":"(2020, October 09). Position Paper of the Italian Association for the Study of the Liver: The Multidisciplinary Clinical Approach to Hepatocellular Carcinoma-AISF-ASSOCIAZIONE ITALIANA STUDIO DEL FEGATO. Available online: https:\/\/www.webaisf.org\/2013\/03\/11\/position-paper-of-the-italian-association-for-the-study-of-the-liver-the-multidisciplinary-clinical-approach-to-hepatocellular-carcinoma\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: Management after the transplant","volume":"20","author":"Verna","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/lt.24042","article-title":"Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation: DONOR FACTORS AND HCC RECURRENCE","volume":"21","author":"Vagefi","year":"2015","journal-title":"Liver Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/hep.27358","article-title":"Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation","volume":"61","author":"Nagai","year":"2015","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/bjs.10080","article-title":"Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis","volume":"103","author":"Orci","year":"2016","journal-title":"Br. J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/jhep.2001.23561","article-title":"Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis","volume":"33","author":"Jonas","year":"2001","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Tsochatzis","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2020.03.018","article-title":"Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant","volume":"73","author":"Cucchetti","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/tri.13983","article-title":"A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: Every nodule matters","volume":"34","author":"Centonze","year":"2021","journal-title":"Transpl. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/lt.20391","article-title":"Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression","volume":"11","author":"Vivarelli","year":"2005","journal-title":"Liver Transpl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma: Heimbach et al","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_25","unstructured":"(2020, October 09). Serum Alpha-Fetoprotein in the Early Stage of Human Hepatocellular Carcinoma-PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/6201411\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/gut.52.suppl_3.iii1","article-title":"British Society of Gastroenterology Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults","volume":"52","author":"Ryder","year":"2003","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"W48","DOI":"10.2214\/AJR.13.12169","article-title":"LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: A pictorial atlas","volume":"203","author":"Jha","year":"2014","journal-title":"Am. J. Roentgenol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s00268-008-9615-8","article-title":"Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection","volume":"32","author":"Zhou","year":"2008","journal-title":"World J. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors: Reassessment of Risk Factors for Tumor Recurrence","volume":"248","author":"Vivarelli","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver Transplantation for Hepatocellular Carcinoma: A Model Including \u03b1-Fetoprotein Improves the Performance of Milan Criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/lt.22039","article-title":"Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria: Prediction of Progression-Free Survival","volume":"16","author":"Vezzoli","year":"2010","journal-title":"Liver Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/hep.28420","article-title":"Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach","volume":"63","author":"Mazzaferro","year":"2016","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Di Sandro, S., Bagnardi, V., Cucchetti, A., Lauterio, A., De Carlis, R., Benuzzi, L., Danieli, M., Botta, F., Centonze, L., and Najjar, M. (2019). From a Philosophical Framework to a Valid Prognostic Staging System of the New \u201cComprehensive Assessment\u201d for Transplantable Hepatocellular Carcinoma. Cancers, 11.","DOI":"10.3390\/cancers11060741"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mahmud, N., John, B., Taddei, T.H., and Goldberg, D.S. (2019). Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality. Clin. Transpl., 33.","DOI":"10.1111\/ctr.13634"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Koch, C., Bette, T., Waidmann, O., Filmann, N., Schrecker, C., Trojan, J., Weiler, N., Vermehren, J., Schnitzbauer, A.A., and Bechstein, W.O. (2020). AFP ratio predicts HCC recurrence after liver transplantation. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235576"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transpl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.30879","article-title":"National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time","volume":"71","author":"Mehta","year":"2020","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jamasurg.2021.0954","article-title":"Dynamic \u03b1-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma","volume":"156","author":"Halazun","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"OLT for HCC Consensus Group Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/5976\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:36:48Z","timestamp":1760168208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/5976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":42,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13235976"],"URL":"https:\/\/doi.org\/10.3390\/cancers13235976","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,27]]}}}